Annals of Family Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Annals of Family Medicine 6:253-262 (2008)
© 2008 Annals of Family Medicine, Inc.
doi: 10.1370/afm.845
This Article
Right arrow Abstract
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow In Brief
Right arrow TRACK Comments: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when TRACK Comments are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Baker, W. L.
Right arrow Articles by Coleman, C. I.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baker, W. L.
Right arrow Articles by Coleman, C. I.

Effect of Nonergot Dopamine Agonists on Symptoms of Restless Legs Syndrome

William L. Baker, PharmD1,2, C. Michael White, PharmD1,2 and Craig I. Coleman, PharmD1,2

1 University of Connecticut School of Pharmacy, Storrs
2 Department of Drug Information, Hartford Hospital, Hartford, Connecticut


Figure 1
View larger version (14K):
[in this window]
[in a new window]

  		Figure 1. Flow diagram of trial identification, inclusion, and exclusion.

IRLS = International Restless Legs Syndrome Study Group Scale score; CGI-I = Clinical Global Impression-Improvement scale.

 

Figure 2
View larger version (13K):
[in this window]
[in a new window]

  		Figure 2. Nonergot dopamine agonist’s impact on response to clinical global impression-improvement scale (A) and International Restless Legs Syndrome Study Group Scale score (B).

CI=confidence interval.

Note: The squares represent individual studies and the size of the square represents the weight given to each study in the meta-analysis. Error bars represent 95% CIs. The diamond represents the combined results. The solid vertical line extending upwards from 0 (CGI) or 1 (IRLS) is the null value.

 

Figure 3
View larger version (11K):
[in this window]
[in a new window]

  		Figure 3. Subgroup and sensitivity analyses of nonergot dopamine agonists evaluating response to Clinical Global Impression-Improvement scale.

CI=confidence interval; DA = dopamine agonists; ITT = intention to treat; NEDA = nonergot dopamine agonist; RR = relative risk.

Note: The dashed vertical line represents the combined treatment effect for the original analysis.

 

Figure 4
View larger version (10K):
[in this window]
[in a new window]

  		Figure 4. Subgroup and sensitivity analyses of nonergot dopamine agonists evaluating mean change in International Restless Legs Syndrome Study Group scale.

CI=confidence interval; DA = dopamine agonists; ITT = intention to treat; NEDA = nonergot dopamine agonist; WMD = weighted mean difference.

Note: The dashed vertical line represents the combined treatment effect for the original analysis.

 

Figure 5
View larger version (12K):
[in this window]
[in a new window]

  		Figure 5. Random-effects meta-regression evaluating effect of NEDAs on mean change in IRLS (A) and CGI-I (B) over time.

NEDAs = nonergot dopamine agonists; IRLS = International Restless Legs Syndrome Study Group Scale; CGI-I = Clinical Global Impression-Improvement; RR=relative risk.

Note: The circles represent individual studies, and the area of the circle is proportional to the weight of each study. The dark line represents the regression equation as represented by the following equation: (A) weighted mean difference = –11.3545 + 0.6574 x study duration; (B) LnRR=0.5304–0.0219 x study duration.

 




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the Annals of Family Medicine.